CELLINK, a biotechnology company, completed the acquisition of Scienion, a company that manufactures life science products, for $94m. The total purchase price of 100 % of Scienion’s shares on cash- and debt-free basis amounts to $94m, $47m paid in cash and $47m paid by the issue of the 2,814,032 Consideration Shares at closing. The Consideration Shares will be covered by lock-up agreements with partial release every 6 months after an initial 12-month period. The total lock-up period for the sellers is between 30 and 36 months. "We are furthering CELLINK’s global commercial strategy by focusing on the patient by providing the most innovative solutions to our customers. With Scienion’s revolutionary technology platforms, we will streamline workflows for our present and future customers, and enhance our presence in the clinical field, a strategy that is well aligned with our long-term vision. Together with Dispendix, cytena, and Scienion, we will be well-positioned to offer comprehensive solutions for academic, pharmaceutical, and clinical customers worldwide," Erik Gatenholm, CELLINK CEO.